Cyclopharm Ltd has released a press release.
USFDA Approval Process Update
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from Cyclopharm
- Cyclopharm 2023 Half Year Accounts Update - Record Revenues
- Notification of buy-back - CYC
- Cyclopharm Confirms USFDA Scheduled Inspection Date
- USFDA Confirms Technegas Six Month Review Period
- Technegas Enters Final Six Month USFDA Review Cycle
Later from Cyclopharm
- Half Year Accounts
- Litigation Update and Receipt of Settlement Payment
- Cyclopharm Investor Update
- Investor Presentation Correction
- Cyclopharm Receives USFDA Approval for Technegas
Follow Cyclopharm into a list and get an email when it puts out news.
Follow Cyclopharm